---
title: "Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293344159.md"
description: "Our strategic plan is progressing towards developing a new therapeutic drug class utilizing a synthetic recombinant Platelet-Rich Plasma (PRP). This innovative approach targets various chronic diseases and is a pivotal step forward in advancing healthcare. By harnessing the power of synthetic PRP, we aim to enhance treatment options and improve patient outcomes. This milestone signifies a significant advancement in medical research and holds promise for addressing a wide range of health conditions."
datetime: "2026-07-21T12:32:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293344159.md)
  - [en](https://longbridge.com/en/news/293344159.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293344159.md)
---

# Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal

Our strategic plan is progressing towards developing a new therapeutic drug class utilizing a synthetic recombinant Platelet-Rich Plasma (PRP). This innovative approach targets various chronic diseases and is a pivotal step forward in advancing healthcare. By harnessing the power of synthetic PRP, we aim to enhance treatment options and improve patient outcomes. This milestone signifies a significant advancement in medical research and holds promise for addressing a wide range of health conditions.

### Related Stocks

- [PPCB.US](https://longbridge.com/en/quote/PPCB.US.md)
- [PPCBD.US](https://longbridge.com/en/quote/PPCBD.US.md)

## Related News & Research

- [GLP-1 drugs could reduce long-term sick leave: Study](https://longbridge.com/en/news/293847884.md)
- [How Investors May Respond To BioCryst (BCRX) Hiring Its First CSO To Drive Rare-Disease Deals](https://longbridge.com/en/news/293587966.md)
- [Clear Secure (YOU) Could Be 16% Undervalued Following Its Healthcare Partnership](https://longbridge.com/en/news/293812923.md)
- [Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials](https://longbridge.com/en/news/293607076.md)
- [FDA advisers recommend against the first unapproved peptide on second day of meeting](https://longbridge.com/en/news/293780907.md)